The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
<b>Introduction</b>: Non-small cell lung cancer (NSCLC) is the second most common cancer globally. The mesenchymal-epithelial transition (MET) proto-oncogene can be targeted in NSCLC patients. <b>Methods</b>: We performed a literature search on PubMed in December 2019 for stu...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/6/1918 |
| _version_ | 1797564750729576448 |
|---|---|
| author | Ramon Andrade De Mello Nathália Moisés Neves Giovanna Araújo Amaral Estela Gudin Lippo Pedro Castelo-Branco Daniel Humberto Pozza Carla Chizuru Tajima Georgios Antoniou |
| author_facet | Ramon Andrade De Mello Nathália Moisés Neves Giovanna Araújo Amaral Estela Gudin Lippo Pedro Castelo-Branco Daniel Humberto Pozza Carla Chizuru Tajima Georgios Antoniou |
| author_sort | Ramon Andrade De Mello |
| collection | DOAJ |
| description | <b>Introduction</b>: Non-small cell lung cancer (NSCLC) is the second most common cancer globally. The mesenchymal-epithelial transition (MET) proto-oncogene can be targeted in NSCLC patients. <b>Methods</b>: We performed a literature search on PubMed in December 2019 for studies on MET inhibitors and NSCLC. Phase II and III clinical trials published in English between 2014 and 2019 were selected. <b>Results</b>: Data on MET inhibitors (tivantinib, cabozantinib, and crizotinib) and anti-MET antibodies (emibetuzumab and onartuzumab) are reported in the text. <b>Conclusion</b>: Emibetuzumab could be used for NSCLC cases with high <i>MET</i> expression. Further, studies on onartuzumab failed to prove its efficacy, while the results of tivantinib trials were clinically but not statistically significant. Additionally, cabozantinib was effective, but adverse reactions were common, and crizotinib was generally well-tolerated. |
| first_indexed | 2024-03-10T19:02:19Z |
| format | Article |
| id | doaj.art-86db5a59675c4c26acd8ecb183395f9f |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T19:02:19Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-86db5a59675c4c26acd8ecb183395f9f2023-11-20T04:20:36ZengMDPI AGJournal of Clinical Medicine2077-03832020-06-0196191810.3390/jcm9061918The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung CancerRamon Andrade De Mello0Nathália Moisés Neves1Giovanna Araújo Amaral2Estela Gudin Lippo3Pedro Castelo-Branco4Daniel Humberto Pozza5Carla Chizuru Tajima6Georgios Antoniou7Algarve Biomedical Centre, Department of Biomedical Sciences and Medicine University of Algarve (DCBM UALG), 8005-139 Faro, PortugalDivision of Medical Oncology, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP), São Paulo 04037-004, BrazilDivision of Medical Oncology, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP), São Paulo 04037-004, BrazilSchool of Biomedical Sciences, Santo Amaro University, São Paulo 01525-000, BrazilAlgarve Biomedical Centre, Department of Biomedical Sciences and Medicine University of Algarve (DCBM UALG), 8005-139 Faro, PortugalDepartment of Biomedicine & I3S, Faculty of Medicine, University of Porto (FMUP), 4200-317 Porto, PortugalHospital São José & Hospital São Joaquim, A Beneficência Portuguesa de São Paulo, São Paulo 01323-001, BrazilDivision of Medical Oncology, Mount Vernon Cancer Center, London HA6 2RN, UK<b>Introduction</b>: Non-small cell lung cancer (NSCLC) is the second most common cancer globally. The mesenchymal-epithelial transition (MET) proto-oncogene can be targeted in NSCLC patients. <b>Methods</b>: We performed a literature search on PubMed in December 2019 for studies on MET inhibitors and NSCLC. Phase II and III clinical trials published in English between 2014 and 2019 were selected. <b>Results</b>: Data on MET inhibitors (tivantinib, cabozantinib, and crizotinib) and anti-MET antibodies (emibetuzumab and onartuzumab) are reported in the text. <b>Conclusion</b>: Emibetuzumab could be used for NSCLC cases with high <i>MET</i> expression. Further, studies on onartuzumab failed to prove its efficacy, while the results of tivantinib trials were clinically but not statistically significant. Additionally, cabozantinib was effective, but adverse reactions were common, and crizotinib was generally well-tolerated.https://www.mdpi.com/2077-0383/9/6/1918NSCLCMETtargeted therapypharmacogenomicspredictive biomarker |
| spellingShingle | Ramon Andrade De Mello Nathália Moisés Neves Giovanna Araújo Amaral Estela Gudin Lippo Pedro Castelo-Branco Daniel Humberto Pozza Carla Chizuru Tajima Georgios Antoniou The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer Journal of Clinical Medicine NSCLC MET targeted therapy pharmacogenomics predictive biomarker |
| title | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer |
| title_full | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer |
| title_fullStr | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer |
| title_full_unstemmed | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer |
| title_short | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer |
| title_sort | role of met inhibitor therapies in the treatment of advanced non small cell lung cancer |
| topic | NSCLC MET targeted therapy pharmacogenomics predictive biomarker |
| url | https://www.mdpi.com/2077-0383/9/6/1918 |
| work_keys_str_mv | AT ramonandradedemello theroleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT nathaliamoisesneves theroleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT giovannaaraujoamaral theroleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT estelagudinlippo theroleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT pedrocastelobranco theroleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT danielhumbertopozza theroleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT carlachizurutajima theroleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT georgiosantoniou theroleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT ramonandradedemello roleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT nathaliamoisesneves roleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT giovannaaraujoamaral roleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT estelagudinlippo roleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT pedrocastelobranco roleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT danielhumbertopozza roleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT carlachizurutajima roleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer AT georgiosantoniou roleofmetinhibitortherapiesinthetreatmentofadvancednonsmallcelllungcancer |